Limits...
Insulin-egg yolk dispersions in self microemulsifying system.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Bottom Line: The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %.Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Formulation of insulin into a microemulsion very often presents a physicochemical instability during their preparation and storage. In order to overcome this lack of stability and facilitate the handling of these colloidal systems, stabilization of insulin in presence of hydrophobic components of a microemulsion appears as the most promising strategy. The present paper reports the use of egg yolk for stabilization of insulin in self microemulsifying dispersions. Insulin loaded egg yolk self microemulsifying dispersions were prepared by lyophilization followed by dispersion into self microemulsifying vehicle. The physicochemical characterization of selfmicroemulsifying dispersions includes such as insulin encapsulation efficiency, in vitro stability of insulin in presence of proteolytic enzymes and in vitro release. The biological activity of insulin from the dispersion was estimated by enzyme-linked immunosorbant assay and in vivo using Wistar diabetic rats. The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %. Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.


Serum human insulin versus time profileSerum human insulin levels after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040865&req=5

Figure 0003: Serum human insulin versus time profileSerum human insulin levels after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.

Mentions: In vivo studies in diabetic rats showed that human insulin is able to absorb from InsEY-SMEDS dispersions as indicated by serum human insulin concentrations over a period of 4 to 12 h as compared to placebo dispersions. However the serum human insulin concentrations levels were lower than the subcutaneous injection for insulin solution. Fig. 3 shows the serum human insulin concentration profile versus time for each group. The pharmacokinetic parameters such as Cmax, Tmax, AUC0-t, T½ were estimated for each group and the values observed are reported in Table 2. From area under human insulin concentration curves, AUC0-12h for 20 IU/kg dose of InsEY-SMEDS formulation was lower than subcutaneous injection (SC. Inj.) of 2 IU/kg. The bioavailability of human insulin from subcutaneous injection was found to be diminished with subcutaneous injection of insulin solution while insulin from InsEY-SMEDS dispersions seemed to be continuing its absorption and hypoglycemic activity (fig. 3).


Insulin-egg yolk dispersions in self microemulsifying system.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Serum human insulin versus time profileSerum human insulin levels after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040865&req=5

Figure 0003: Serum human insulin versus time profileSerum human insulin levels after intragastric administration of 20 IU/kg InsEY-SMEDS dispersion (▪), Placebo formulation of InsEY-SMEDS equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group.
Mentions: In vivo studies in diabetic rats showed that human insulin is able to absorb from InsEY-SMEDS dispersions as indicated by serum human insulin concentrations over a period of 4 to 12 h as compared to placebo dispersions. However the serum human insulin concentrations levels were lower than the subcutaneous injection for insulin solution. Fig. 3 shows the serum human insulin concentration profile versus time for each group. The pharmacokinetic parameters such as Cmax, Tmax, AUC0-t, T½ were estimated for each group and the values observed are reported in Table 2. From area under human insulin concentration curves, AUC0-12h for 20 IU/kg dose of InsEY-SMEDS formulation was lower than subcutaneous injection (SC. Inj.) of 2 IU/kg. The bioavailability of human insulin from subcutaneous injection was found to be diminished with subcutaneous injection of insulin solution while insulin from InsEY-SMEDS dispersions seemed to be continuing its absorption and hypoglycemic activity (fig. 3).

Bottom Line: The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %.Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Formulation of insulin into a microemulsion very often presents a physicochemical instability during their preparation and storage. In order to overcome this lack of stability and facilitate the handling of these colloidal systems, stabilization of insulin in presence of hydrophobic components of a microemulsion appears as the most promising strategy. The present paper reports the use of egg yolk for stabilization of insulin in self microemulsifying dispersions. Insulin loaded egg yolk self microemulsifying dispersions were prepared by lyophilization followed by dispersion into self microemulsifying vehicle. The physicochemical characterization of selfmicroemulsifying dispersions includes such as insulin encapsulation efficiency, in vitro stability of insulin in presence of proteolytic enzymes and in vitro release. The biological activity of insulin from the dispersion was estimated by enzyme-linked immunosorbant assay and in vivo using Wistar diabetic rats. The particle size ranged 1.023±0.316 μm in diameter and insulin encapsulation efficiency was 98.2±0.9 %. Insulin hydrophobic self microemulsifying dispersions suppressed insulin release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Egg yolk encapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.